AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32898838 — intervention group
Group type: EXPERIMENTAL
Intervention: Other products (not specified)
Number of subjects: 0
Study 33162314 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage (15 minutes daily for four days)
Number of subjects: 0
Study 33162314 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 32603618 — intervention group
Group type: EXPERIMENTAL
Intervention: Older hearing-impaired (OHI) listeners
Number of subjects: 20
Study 32603618 — intervention group
Group type: COMPARATOR
Intervention: Older normal-hearing (ONH) listeners
Number of subjects: 20
Study 34537121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block (TAPB)
Number of subjects: 63
Study 34537121 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB)
Number of subjects: 63
Study 34537121 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia alone (Control)
Number of subjects: 63
Study 32472902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma (two units) followed by standard care fluid resuscitation
Number of subjects: 501
Study 32472902 — intervention group
Group type: COMPARATOR
Intervention: Standard care (crystalloid)
Number of subjects: 501
Study 33307377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner-delivered brief intervention (NBI)
Number of subjects: 300
Study 33307377 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention (CBI)
Number of subjects: 300
Study 33307377 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only cohort (historical comparison group)
Number of subjects: 300
Study 32893505 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased loop diuretic dose
Number of subjects: 0
Study 32893505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diuretic therapy (loop diuretic plus chlorothiazide)
Number of subjects: 0
Study 32893505 — intervention group
Group type: COMPARATOR
Intervention: Standard loop diuretic therapy
Number of subjects: 0
Study 36190613 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological traits analysis among eggplant genotypes
Number of subjects: 17
Study 36190613 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR markers analysis
Number of subjects: 17
Study 33849584 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate skin-to-skin contact (SSC)
Number of subjects: 297
Study 33849584 — intervention group
Group type: COMPARATOR
Intervention: Early skin-to-skin contact (SSC)
Number of subjects: 297
Study 35758944 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate (Cereton)
Number of subjects: 0
Study 35758944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34593120 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triple therapy (macitentan, tadalafil, and selexipag)
Number of subjects: 247
Study 34593120 — intervention group
Group type: COMPARATOR
Intervention: Initial double therapy (macitentan, tadalafil, and placebo)
Number of subjects: 247
Study 35569079 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy with intracorporeal reconstruction
Number of subjects: 338
Study 35569079 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 338
Study 35569079 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy
Number of subjects: 338
Study 34273682 — intervention group
Group type: EXPERIMENTAL
Intervention: Juçara fruit juice (JFJ) 250 mL
Number of subjects: 15
Study 34273682 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study 33559485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 21162
Study 33559485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study 32041605 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological with best practice prevention (B+P)
Number of subjects: 1058
Study 32041605 — intervention group
Group type: COMPARATOR
Intervention: Prevention Alone (PA)
Number of subjects: 1058
Study 32041605 — intervention group
Group type: COMPARATOR
Intervention: Conventional with best practice prevention (C+P)
Number of subjects: 1058
Study 34139916 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32248829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (subcutaneously at 162 mg/week)
Number of subjects: 120
Study 32248829 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (orally at 10 mg/day)
Number of subjects: 120
Study 32248829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 120
Study 32248829 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 120
Study 32248829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab and Prednisone
Number of subjects: 120
Study 34961729 — intervention group
Group type: EXPERIMENTAL
Intervention: app + telehealth
Number of subjects: 37
Study 34961729 — intervention group
Group type: COMPARATOR
Intervention: app
Number of subjects: 37
Study 34237274 — intervention group
Group type: EXPERIMENTAL
Intervention: Point mutations abrogating spectrin-repeat-mediated dimerization of Kar9
Number of subjects: 0
Study 34237274 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphomimetic substitution of six Cdk1 sites surrounding the Kar9 dimerization interface
Number of subjects: 0
Study 32569643 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare
Number of subjects: 288
Study 32569643 — intervention group
Group type: COMPARATOR
Intervention: SAU
Number of subjects: 288
Study 32234011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment and accelerometer use for measuring physical activity (PA)
Number of subjects: 0
Study 32234011 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments followed by three annual follow-up assessments
Number of subjects: 0
Study 35193718 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil and cashew nuts group (BN-Group): Energy-restricted diet containing daily 45 g of nuts (15 g of Brazil nuts + 30 g of cashew nuts), n=21
Number of subjects: 40
Study 35193718 — intervention group
Group type: COMPARATOR
Intervention: Control group: Energy-restricted diet without nuts, n=19
Number of subjects: 40
Study 34412536 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-control group (scapular-focused exercise + conscious control of scapular orientation)
Number of subjects: 36
Study 34412536 — intervention group
Group type: COMPARATOR
Intervention: Regular-exercise group (scapular-focused exercises only)
Number of subjects: 36
Study 33052965 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (MAP) consisting of 2.5 trauma-focused psychotherapy sessions and two 8-hour sessions with MDMA (mean dose of 125 mg) followed by 3.5 integration sessions
Number of subjects: 105
Study 33052965 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (MAP)
Number of subjects: 105
Study 33052965 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo or 25–40 mg of MDMA
Number of subjects: 105
Study 34281074 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Physical Guidance (PG)
Number of subjects: 25
Study 34281074 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% Physical Guidance (PG)
Number of subjects: 25
Study 34281074 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Physical Guidance (PG)
Number of subjects: 25
Study 34281074 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Physical Guidance (PG)
Number of subjects: 25
Study 34281074 — intervention group
Group type: COMPARATOR
Intervention: 0% Physical Guidance (PG)
Number of subjects: 25
Study 35166212 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point therapy (TriT)
Number of subjects: 100
Study 35166212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint therapy (AcuT)
Number of subjects: 100
Study 33378499 — intervention group
Group type: EXPERIMENTAL
Intervention: Connecticut intrusion arch (CIA) without a cinch back
Number of subjects: 44
Study 33378499 — intervention group
Group type: COMPARATOR
Intervention: Connecticut intrusion arch (CIA) with a cinch back
Number of subjects: 44
Study 34933532 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) consumption
Number of subjects: 200
Study 34933532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC consumption)
Number of subjects: 200
Study 34677153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone group (received lung disinfection technique with ozone and standard COVID-19 treatment)
Number of subjects: 30
Study 34677153 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with ozone, only received standard COVID-19 treatment)
Number of subjects: 30
Study 34962461 — intervention group
Group type: EXPERIMENTAL
Intervention: A connection mode (pre‐membrane‐pre‐pump connection)
Number of subjects: 21
Study 34962461 — intervention group
Group type: EXPERIMENTAL
Intervention: B connection mode (post‐membrane‐post‐pump connection)
Number of subjects: 21
Study 34962461 — intervention group
Group type: COMPARATOR
Intervention: Both connection modes
Number of subjects: 21
Study 36608971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week online intervention with three functionality-focused writing exercises
Number of subjects: 103
Study 36608971 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 103
Study 36608971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 103
Study 32949144 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with saline (n = 15)
Number of subjects: 45
Study 32949144 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with saline followed by corticosteroid application (triamcinolone acetonide in saline) (saline/TA, n = 15)
Number of subjects: 45
Study 32949144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation, n = 15)
Number of subjects: 45
Study 32464266 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional photodynamic therapy (C‐PDT)
Number of subjects: 30
Study 32464266 — intervention group
Group type: COMPARATOR
Intervention: Daylight photodynamic therapy (DL‐PDT)
Number of subjects: 30
Study 32464266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 34838460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Number of subjects: 0
Study 34838460 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Number of subjects: 0
Study 33864735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 μg per actuation, total dose of 1600 μg, two puffs twice per day)
Number of subjects: 139
Study 33864735 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study 33710277 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg CBD and 5.4 mg THC daily
Number of subjects: 43
Study 33710277 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg CBD and 10.8 mg THC daily
Number of subjects: 43
Study 33710277 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg CBD and 16.2 mg THC daily
Number of subjects: 43
Study 33710277 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg CBD and 21.6 mg THC daily
Number of subjects: 43
Study 33710277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 34329455 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil + Pregabalin (300 mg orally)
Number of subjects: 31
Study 34329455 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 31
Study 35767811 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning algorithms for predicting conversion to arthroplasty
Number of subjects: 875
Study 35767811 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw or cancellous screws for internal fixation (control)
Number of subjects: 875
Study 33383228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control strategies
Number of subjects: 4060
Study 33383228 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategies
Number of subjects: 4060
Study 35760666 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-cross-linked hyaluronic acid gel
Number of subjects: 171
Study 35760666 — intervention group
Group type: COMPARATOR
Intervention: Control (oestradiol and intrauterine balloon insertion)
Number of subjects: 171
Study 34146646 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 510
Study 34146646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 510
Study 34146646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510
Study 34146646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional warnings
Number of subjects: 510
Study 34146646 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related cues (nutrient claims and images of seeds and wheat)
Number of subjects: 510
Study 35149565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 180
Study 35149565 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 180
Study 35149565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 180
Study 33612282 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 496
Study 33612282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 35246416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention led by trained health extension workers every 2 months for 9 months
Number of subjects: 456
Study 35246416 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 456
Study 35246416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention led by trained health extension workers
Number of subjects: 456
Study 32045316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocarbon group (n=51)
Number of subjects: 93
Study 32045316 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 93
Study 36226670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand grip training program (HG)
Number of subjects: 0
Study 36226670 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CG)
Number of subjects: 0
Study 33990144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly)
Number of subjects: 832
Study 33990144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (monthly)
Number of subjects: 832
Study 33990144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 832
Study 32314464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (20 mg/day)
Number of subjects: 64
Study 32314464 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (0.5 mg/day)
Number of subjects: 64
Study 32314464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Number of subjects: 64
Study 32314464 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 64
Study 36445874 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid pre-workout beverage (490 mg)
Number of subjects: 12
Study 36445874 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid pre-workout beverage (5 mg)
Number of subjects: 12
Study 33945820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproxalap 0.25%
Number of subjects: 318
Study 33945820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproxalap 0.5%
Number of subjects: 318
Study 33945820 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 318
Study 35594564 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19
Number of subjects: 0
Study 35594564 — intervention group
Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 0
Study 33735740 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz active rTMS stimulation
Number of subjects: 38
Study 33735740 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS stimulation
Number of subjects: 38
Study 32979294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness app (10–20 min/day) or webinar‐based mindfulness course for 6 weeks
Number of subjects: 142
Study 32979294 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (usual care)
Number of subjects: 142
Study 34980546 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg), Vitamin D3 (400 IU), Collagen Peptides (5 g)
Number of subjects: 51
Study 34980546 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg), Vitamin D3 (400 IU)
Number of subjects: 51
Study 32394651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Shenmen (HT 7) and Baihui (GV 20) in group A
Number of subjects: 333
Study 32394651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sanyinjiao (SP 6) and Baihui (GV 20) in group B
Number of subjects: 333
Study 32394651 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non‐acupoint and Baihui (GV 20) in group C
Number of subjects: 333
Study 34687122 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week supervised therapeutic exercise program
Number of subjects: 19
Study 34687122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 36190598 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA (Group B)
Number of subjects: 66
Study 36190598 — intervention group
Group type: COMPARATOR
Intervention: Turbo flash scan using iohexol (Group A)
Number of subjects: 66
Study 36190598 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA (Group C)
Number of subjects: 66
Study 36190598 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA (Group C40keV)
Number of subjects: 66
Study 33990969 — intervention group
Group type: COMPARATOR
Intervention: TAK-418 (5-60 mg single rising dose)
Number of subjects: 54
Study 33990969 — intervention group
Group type: COMPARATOR
Intervention: TAK-418 (120-160 mg single rising dose)
Number of subjects: 54
Study 33990969 — intervention group
Group type: COMPARATOR
Intervention: TAK-418 (20-160 mg once daily for 10 days)
Number of subjects: 54
Study 33990969 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-418
Number of subjects: 54
Study 32698830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 72
Study 32698830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic glucocorticoids
Number of subjects: 72
Study 32698830 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vestibular dysfunction symptoms
Number of subjects: 72
Study 35231887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (100 mg daily)
Number of subjects: 48
Study 35231887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aluminum hydroxide suspension, 2.5 ml daily)
Number of subjects: 48
Study 33400092 — intervention group
Group type: EXPERIMENTAL
Intervention: HAdV‐7 strains from children with ARI
Number of subjects: 57
Study 33400092 — intervention group
Group type: EXPERIMENTAL
Intervention: HAdV‐7 strains
Number of subjects: 57
Study 34340694 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for up to 3 months postpartum offering up to £120 of incentives (£60 for the participant and £60 for a significant other support)
Number of subjects: 0
Study 34340694 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for up to 12 months postpartum with up to £300 of incentives (£240 for the participant and £60 for a significant other support)
Number of subjects: 0
Study 34340694 — intervention group
Group type: COMPARATOR
Intervention: No incentives/usual care
Number of subjects: 0
Study 34798073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges
Number of subjects: 182
Study 34798073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 182
Study 34676982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgolide
Number of subjects: 936
Study 34676982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study 35451544 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning as a self-regulation strategy
Number of subjects: 19
Study 35451544 — intervention group
Group type: COMPARATOR
Intervention: Not planning
Number of subjects: 19
Study 36141910 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred intervention 'Are you too sweet?'
Number of subjects: 24
Study 36141910 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention semi-structured interviews
Number of subjects: 24
Study 33704919 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg every 6 hours)
Number of subjects: 0
Study 33704919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxic acid (PDA) and homovanillic acid (HVA) as biomarkers
Number of subjects: 0
Study 33704919 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA model
Number of subjects: 0
Study 33704919 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based simulations and power calculations
Number of subjects: 0
Study 36041982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training with a mechanical threshold device in addition to usual care
Number of subjects: 70
Study 36041982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study 32978652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing via suprapatellar approach (IMN group)
Number of subjects: 328
Study 32978652 — intervention group
Group type: COMPARATOR
Intervention: Locked compressive plate (LCP group)
Number of subjects: 328
Study 32589828 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe (200 mg) plus Lactobacillus plantarum HEAL9 (1 × 10⁹ CFU)
Number of subjects: 90
Study 32589828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35749277 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 565
Study 35749277 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 565
Study 33735206 — intervention group
Group type: EXPERIMENTAL
Intervention: AGL-FTIC
Number of subjects: 693